secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001193125-25-028123
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences reports 110% avg microdystrophin expression from SGT-003 Phase 1/2 trial
--------------------------------------------------------------------------------

- First three participants showed average 110% microdystrophin expression by western blot and 78% dystrophin-positive fibers at Day 90.
- Mean reductions in muscle injury biomarkers: CK -57%, AST -45%, ALT -54%, LDH -60% at Day 90.
- Two participants at Day 180 showed mean LVEF increase of 8% from baseline; no serious adverse events or TMA observed.
- Preliminary cash, cash equivalents and available-for-sale securities of ~$148.9M as of Dec 31, 2024.
- Company plans mid-2025 FDA meeting to discuss accelerated approval for SGT-003; enrollment ongoing with 7th dosed Feb 17.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312525028123/0001193125-25-028123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312525028123/d913726d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-028123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer